Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in EU for leukemia

 The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting 

BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor

https://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-union-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-previously-treated-with-a-btk-inhibitor-302388582.html